{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032412","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.036120+00:00","generated_at":"2026-05-31T09:14:07.958729+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elite Pharma Q1 FY2025 revenue up 109% YoY to $18.8M; operating profit +144%","bullets":["Revenue of $18.8M for Q1 ended June 30, 2024, compared to $9.0M in Q1 FY2024.","Operating profit rose to $3.9M from $1.6M YoY, a 144% increase.","Net income attributable to common shareholders was $0.6M.","Growth driven by higher sales of Elite label product line.","Conference call scheduled for August 15, 2024 at 11:30 AM EDT."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032412","json":"https://secwatch.observer/filing/0001493152-24-032412.json","markdown":"https://secwatch.observer/filing/0001493152-24-032412.md","text":"https://secwatch.observer/filing/0001493152-24-032412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224032412/0001493152-24-032412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224032412/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:14:07.958729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}